(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 15.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 256.88%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.88%.
Niagen Bioscience's revenue in 2025 is $116,303,000.On average, 1 Wall Street analysts forecast NAGE's revenue for 2025 to be $10,080,773,765, with the lowest NAGE revenue forecast at $10,080,773,765, and the highest NAGE revenue forecast at $10,080,773,765. On average, 2 Wall Street analysts forecast NAGE's revenue for 2026 to be $12,317,844,209, with the lowest NAGE revenue forecast at $12,034,721,211, and the highest NAGE revenue forecast at $12,600,967,206.
In 2027, NAGE is forecast to generate $14,546,939,357 in revenue, with the lowest revenue forecast at $14,546,939,357 and the highest revenue forecast at $14,546,939,357.